At ASCO 2013 Daniel D. Van Hoff, MD, Physician-In-Chief of the Translational Genomics Research Institute (TGen), presented the data for the phase III pancreatic cancer MPACT trial that compared weekly nab-paclitaxel (Abraxane) plus gemcitabine (Gem) versus gemcitabine alone (ASCO 2013 Abstract 4005). The results were first presented at the ASCO GI meeting earlier this year.

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase personal access to all Premium Content. Current subscription rate is $399 for 3 months access and $1200 for 12 months access. Please contact us if you would like to purchase annual access. Subscriptions do not auto renew. Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals.